Sonic Healthcare (SHL) H2 2024 earnings summary

Executive summary

• FY 2024 marked a transition from pandemic disruption to normalized operations, with total revenue rising 10% to A$8,967M, driven by 16% growth in base business revenue and major acquisitions, while COVID-related revenue declined sharply.

• Organic revenue growth remained robust at 6%, underpinned by medical leadership, strategic M&A activity in Germany, Switzerland, and the USA, and contract wins.

• Post-pandemic headcount reduction program is largely complete, optimizing cost structure for future growth.

• EBITDA (excluding US West division sale) was A$1,602M, down 6% year-over-year but in line with guidance; net profit fell 25% to A$511M.

• Cash generation remained strong, with 95% EBITDA conversion to gross operating cash flow.

Financial highlights

• Total revenue for FY 2024 was just under AUD 9 billion; base business revenue reached A$8,905M, up 16% year-over-year.

• COVID-related revenue dropped from nearly AUD 500 million in FY 2023 to AUD 62 million in FY 2024.

• EBITDA margin expanded in H2 FY 2024 compared to H1; EBITDA reached AUD 1.602 billion, in line with prior guidance.

• Acquisitions contributed AUD 655 million in new annual revenue.

• Final dividend of AUD 0.63 per share (up 2%), total annual dividend AUD 1.06 per share (up 2%).

Outlook and guidance

• FY 2025 EBITDA guidance: AUD 1.7–1.75 billion (constant currency), reflecting up to 10% growth.

• Interest expense expected to rise 25% due to acquisitions; effective tax rate projected at 26–27%.

• Guidance includes AUD 15 million potential PAMA fee cuts in the USA and an initial AUD 10 million loss from a new UK contract, both with future profitability expected.

• July 2024 trading in line with budget; guidance includes only completed acquisitions and assumes current interest rates.

• Depreciation as a percentage of revenue to remain stable.